European Committee for Treatment and Research in Multiple Sclerosis

Assessing Antibody, Cellular Response to COVID-19 Vaccines in Ocrelizumab-Treated Patients: Ilya Kister, MD

October 18, 2021

The professor of neurology at the NYU Grossman School of Medicine discussed the trial design of VIOLA, a new prospective study evaluating responses to COVID-19 vaccines in patients with MS on ocrelizumab (Ocrevus; Genentech). [WATCH TIME: 3 minutes]

Expanded Data from ULTIMATE 1 and 2 Trials of Ublituximab: Lawrence Steinman, MD

October 15, 2021

The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University spoke on the safety and efficacy of ublituximab in treating patients with relapsing forms of multiple sclerosis. [WATCH TIME: 4 minutes]

Real-World Ofatumumab Use Highlighted Post-Approval for MS

October 15, 2021

The vast majority of patients with MS, 63.4%, who initiated ofatumumab treatment in the 6 months after its approval had mild disability, while only 29.2% had moderate disability and 7.4% had severe disability.